Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells
Open Access
- 3 July 2014
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 57 (9) , 1968-1976
Abstract
Impaired angiogenesis induced by vascular endothelial growth factor (VEGF) resistance is a hallmark of vascular complications in type 2 diabetes; however, its molecular mechanism is not fully understood. We have previously identified selenoprotein P (SeP, encoded by the SEPP1 gene in humans) as a liver-derived secretory protein that induces insulin resistance. Levels of serum SeP and hepatic expression of SEPP1 are elevated in type 2 diabetes. Here, we investigated the effects of SeP on VEGF signalling and angiogenesis.Keywords
This publication has 42 references indexed in Scilit:
- Peripheral arterial disease in diabetes—a reviewDiabetic Medicine, 2010
- Therapeutic Angiogenesis in Diabetes and Hypercholesterolemia: Influence of Oxidative StressAntioxidants & Redox Signaling, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Impact of Diabetes on Five-Year Outcomes of Patients With Multivessel Coronary Artery DiseaseThe Annals of Thoracic Surgery, 2007
- Angiogenesis, Arteriogenesis, and DiabetesJACC, 2005
- Topical Vascular Endothelial Growth Factor Accelerates Diabetic Wound Healing through Increased Angiogenesis and by Mobilizing and Recruiting Bone Marrow-Derived CellsThe American Journal of Pathology, 2004
- Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among menThe American Journal of Medicine, 2004
- Effect of Diabetes Mellitus on Formation of Coronary Collateral VesselsCirculation, 1999
- Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy materialThe Journal of Pathology, 1992